Last updated on April 2019

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Brief description of study

The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with REGN2810 as a monotherapy

Clinical Study Identifier: NCT03132636

Find a site near you

Start Over

Norton Cancer Institute

Louisville, KY United States
  Connect »

Overlook Medical Center

Summit, NJ United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »

Hopital Ambroise Pare

Boulogne Billancourt, France
  Connect »

Institut Gustave Roussy

Villejuif Cedex, France
  Connect »